Doyle Ramona 4
4 · RECURSION PHARMACEUTICALS, INC. · Filed Apr 4, 2022
Insider Transaction Report
Form 4
Doyle Ramona
Chief Medical Officer
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2022-03-31−9,072→ 669,356 totalExercise: $2.48Exp: 2030-12-30→ Class A Common Stock (669,356 underlying) - Exercise/Conversion
Class A Common Stock
2022-03-31$2.48/sh+9,072$22,499→ 121,942 total
Holdings
- 4,784
Stock Option (Right to Buy)
Exercise: $11.40From: 2022-02-04Exp: 2032-02-04→ Class A Common Stock (4,784 underlying) - 76,998
Stock Option (Right to Buy)
Exercise: $11.40Exp: 2032-02-04→ Class A Common Stock (76,998 underlying)
Footnotes (2)
- [F1]Twenty-Five percent (25%) of the 750,000 shares originally subject to the award shall vest one year after December 31, 2020, or the Vesting Commencement Date, and one-forty-eighth (148th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Vesting Commencement Date.
- [F2]The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.